Streetbeat News

Revenues

FULC

Fulcrum Therapeutics (NASDAQ:FULC) reported Q2 earnings of $0.87 per share, a significant improvement from a $(0.38) loss YoY. However, the company missed sales estimates by 99.71%, reporting $80,000 in sales compared to the expected $27.66 million. The company exits the quarter with $273.8 million in cash and equivalents.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:08 am

DAY

Dayforce has announced its FY24 revenue guidance, projecting between $1.736 billion and $1.746 billion, slightly above the estimated $1.735 billion.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:08 am

DAY

Dayforce has projected its Q3 2024 revenue to be between $425 million and $430 million, which is slightly below the estimated $430.542 million.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:08 am

SHOO

Steve Madden expects FY24 revenue to increase by 11% to 13% and adjusted EPS to be between $2.55 and $2.65, with an estimate of $2.64.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:07 am

LVO

LYV

MUSQ

Live Nation Entertainment Inc (LYV) reported mixed Q2 earnings, with EPS missing estimates but revenue slightly exceeding expectations. Despite economic challenges, Live Nation saw a 7% YoY revenue increase and a 21% rise in operating income. The MUSQ Global Music Industry ETF (MUSQ) offers diversified exposure to the music industry, including holdings in LYV and LiveOne Inc (LVO). MUSQ is currently trading near its 200-day moving average, presenting potential upside targets for investors.

Portfolio Pulse from Joshenomoto@benzinga.com

July 31, 2024 | 11:06 am

MAR

Marriott International has provided its Q3 2024 financial outlook, projecting gross fee revenues between $1.275 billion and $1.29 billion and adjusted EPS between $2.27 and $2.33, which is below the $2.38 estimate.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:06 am

TEVA

Teva Pharmaceutical has updated its 2024 revenue guidance to $16.0B-$16.4B, up from the previous $15.7B-$16.3B and above the consensus of $16.012B. Key product revenue projections have also been adjusted, with AUSTEDO expected to generate ~$1,600M, up from ~$1,500M, and COPAXONE expected to generate ~$450M, up from ~$400M. Other financial metrics such as operating income, adjusted EBITDA, and diluted EPS have seen slight improvements.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:06 am

AMRN

Amarin has reiterated that for FY24, it believes its current cash, investments, and other assets are adequate to support continued operations.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:06 am

DFIN

Donnelley Financial Solutions (NYSE:DFIN) reported Q2 earnings of $1.66 per share, beating the analyst estimate of $1.40. However, sales of $242.70 million missed the estimate of $244.62 million.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:05 am

BXP

BXP announced it signed approximately 1.3 million square feet of leases in Q2 2024 with an average lease term of 9 years, bringing total leasing activity for 2024 to around 2.2 million square feet.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 11:05 am